SecBot SecBot
SECBOTREPLAY Home › Report › COLL

COLL · Collegium reported Q2 2026 adjusted EPS of $1.92, beating the Street…

COLLEGIUM PHARMACEUTICAL, INC · 8-K filed Aug 6, 2026 at 07:33 ET

At the news

MIXEDIMPACT 6/10

8-K filed Aug 6, 2026 at 07:33 ET

Collegium reported Q2 2026 adjusted EPS of $1.92, beating the Street consensus of $1.48 by 29.7%, and revenue of $199.9M (+6% YoY). However, the company lowered full-year 2026 product revenue guidance to $825-855M (from $865-895M) and adjusted EBITDA to $445-470M (from $475-500M), citing weaker-than-expected authorized generic Nucynta pricing. The GAAP net loss of ($15.1M) reflects acquisition-related costs from the recently closed AZSTARYS deal. The ADHD portfolio (JORNAY PM +41% YoY, AZSTARYS $12.9M partial quarter) is strong, but the pain portfolio declined 9% YoY, creating a mixed outlook.

  • Q2 2026 adjusted EPS $1.92 vs consensus $1.48, beat 29.7%
  • Q2 2026 revenue $199.9M, +6% YoY
  • GAAP net loss ($15.1M) due to acquisition-related expenses and amortization
  • Completed AZSTARYS acquisition in May; added $12.9M in partial quarter revenue

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access